Amgen Sjogrens Drug Succeeds in Late-Stage Trial
Amgen reported that its experimental drug dazodalibep met its main goal in a late-stage trial for Sjogrens disease. The treatment showed significant improvement in patients with moderate-to-severe activity. Shares rose four percent in morning trading.
Xurve View
Insights:
Xurve View
AMGEN INC reported that its experimental drug dazodalibep met its main goal in a late-stage trial, lifting its shares 4% in morning trading. The treatment targets Sjogrens disease, an autoimmune condition that attacks moisture-producing glands.
